ReviewBiomolecules2020
Anticancer Potential of Lichens' Secondary Metabolites.
Review in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effect of lichen secondary metabolites on Aspergillus fungi.Archives of microbiology · 2021Pooled it
- Anticancer activity of lichen-derived compounds against triple-negative breast cancer: integrated in vitro evaluation, network pharmacology, molecular docking, and KEGG pathway analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Evernic and diffractaic acids: Novel regulators of intracellular redox homeostasis in the MCF-7 cell line.Molecular biology reports · 2026Article
- Pro-apoptotic and cell cycle-modulating effects of lobaric and rhizocarpic acids in human leukemic cell lines.Molecular biology reports · 2026Article
- A New Trichlorinated Xanthone and Compounds Isolated fromPharmaceuticals (Basel, Switzerland) · 2026Article
- Inhibition of thioredoxin reductase 1 by evernic and vulpinic acids: a promising anticancer strategy on A549 cells.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Natural product as a lead for impairing mitochondrial respiration in cancer cells.Journal of enzyme inhibition and medicinal chemistry · 2025Article
- Article
- The Brazilian Native Fruits Araçá, Guabijú, and Guabiroba: A Brief and Integrative Review on Their Phenolic Composition and Analytical Methods.Foods (Basel, Switzerland) · 2025Review
- Lobaric Acid Exhibits Anticancer Potential by Modulating the Wnt/β-Catenin Signaling Pathway in MCF-7 Cells.Pharmacology research & perspectives · 2025Article
- In silico identification of PPARγ agonists from diffractaic acid analogs in prostate cancer: a comprehensive computational approach.3 Biotech · 2025Article
- In vitro, in vivo and in silico anticancer activity and toxicity of Usnic acid extracted from the mycobiont culture of Usnea baileyi.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Lichens and Health-Trends and Perspectives for the Study of Biodiversity in the Antarctic Ecosystem.Journal of fungi (Basel, Switzerland) · 2025Review
- Telomeric RNA quadruplexes as targets for cancer prevention: The therapeutic potential of agonodepsides.Journal, genetic engineering & biotechnology · 2025Article
- Development and synthesis of diffractaic acid analogs as potent inhibitors of colorectal cancer stem cell traits.Scientific reports · 2025Article
- Perception, Trust, and Motivation in Consumer Behavior for Organic Food Acquisition: An Exploratory Study.Foods (Basel, Switzerland) · 2025Article
- Delineating the Potential Therapeutic Effects of Lobaric Acid as a Novel Strategy in the Treatment of Melanoma.Current medicinal chemistry · 2025Article
- Antiproliferative and pro-apoptotic effects ofFrontiers in oncology · 2025Article
- Exploring lichen-derived compounds as potential anti-cervical cancer agents: an DFT and MD simulation analysis.In silico pharmacology · 2025Article
- Metabolomic Approach in Anticancer Biomarker Discovery from Foliose Lichens.Advanced pharmaceutical bulletin · 2024Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lichens produce different classes of phenolic compounds, including anthraquinones, xanthones, dibenzofuranes, depsides and depsidones. Many of them have revealed effective biological activities such as antioxidant, antiviral, antibiotics, antifungal, and anticancer. Although no clinical study has been conducted yet, there are number of in vitro and in vivo studies demonstrating anticancer effects of lichen metabolites. The main goal of our work was to review most recent published papers dealing with anticancer activities of secondary metabolites of lichens and point out to their perspective clinical use in cancer management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.